These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 17259805)
1. Correlation between bronchodilator responsiveness and quality of life in chronic obstructive pulmonary disease. Omata M; Wakabayashi R; Kudoh S; Kida K Allergol Int; 2007 Mar; 56(1):15-22. PubMed ID: 17259805 [TBL] [Abstract][Full Text] [Related]
2. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD. Molimard M; Bourcereau J; Le Gros V; Bourdeix I Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485 [TBL] [Abstract][Full Text] [Related]
3. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease. Broseghini C; Testi R; Polese G; Tosatto R; Rossi A Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852 [TBL] [Abstract][Full Text] [Related]
4. Comparison of bronchodilator responsiveness in asthma and chronic obstructive pulmonary disease. Chhabra SK; Bhatnagar S Indian J Chest Dis Allied Sci; 2002; 44(2):91-7. PubMed ID: 12026258 [TBL] [Abstract][Full Text] [Related]
5. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Ben Saad H; Préfaut C; Tabka Z; Zbidi A; Hayot M Pulm Pharmacol Ther; 2008 Oct; 21(5):767-73. PubMed ID: 18555715 [TBL] [Abstract][Full Text] [Related]
6. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD. Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631 [TBL] [Abstract][Full Text] [Related]
7. Quality of life measured by the St George's Respiratory Questionnaire and spirometry. Weatherall M; Marsh S; Shirtcliffe P; Williams M; Travers J; Beasley R Eur Respir J; 2009 May; 33(5):1025-30. PubMed ID: 19164350 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094 [TBL] [Abstract][Full Text] [Related]
9. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Umeda N; Yoshikawa T; Kanazawa H; Hirata K; Fujimoto S Respirology; 2008 May; 13(3):346-52. PubMed ID: 18399855 [TBL] [Abstract][Full Text] [Related]
10. [Bronchial obstruction reversibility test in the assessment of COPD severity--controversies]. Maskey-Warzechowska M; Pankowska M; Chazan R Pneumonol Alergol Pol; 2006; 74(1):68-71. PubMed ID: 17175980 [TBL] [Abstract][Full Text] [Related]
11. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Kuna P; Jenkins M; O'Brien CD; Fahy WA Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578 [TBL] [Abstract][Full Text] [Related]
12. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176 [TBL] [Abstract][Full Text] [Related]